Company research / Focus view

Dr. Reddy's Laboratories

DRREDDY · Pharma & Healthcare · large cap · Nifty 50

Revenue · FY26

₹33,593 cr

+3.2% YoY

What the business sold

Net profit · FY26

₹4,285 cr

-24.2% YoY

What it kept after tax

Operating profit · FY26

₹5,012 cr

-30.4% YoY

Profit from operations

Operating cash flow · FY26

₹5,676 cr

+22.2% YoY

Cash the operations produced

Total debt · FY26

₹7,734 cr

+65.4% YoY

Borrowings against the business

Dividend per share · FY26

—

Paid out per share · not collected yet

Five years in perspective

Price index · Start = 100 · Dividends excluded · ₹1,165.5 today (+1.97%)

+18.6% · 5Y

2021 · 10020222023202420252026 · 125.1

1M -3.3%6M -12.1%1Y -10.6%3Y +3.8%5Y +18.6%

Market cap

₹97,085 Cr

As of 13 Sept 2026

Price to earnings

29.3

Price to book 2.5

Dividend yield

69.00%

Trailing twelve months

52-week range

₹1,101 – ₹1,415

Closing prices

The financial record

₹ crore · Consolidated where reported · Indian fiscal years (April–March)

Reported metric	FY23	FY24	FY25	FY26
Revenue	24,588	27,916	32,554	33,593
Operating profit	5,905	6,531	7,201	5,012
Net profit	4,507	5,568	5,654	4,285
Operating cash flow	5,888	4,543	4,643	5,676
Free cash flow	4,001	1,800	1,203	1,833
Capital expenditure	-1,887	-2,744	-3,440	-3,843
Tax expense	1,530	1,619	1,954	1,235
Total debt	1,347	2,002	4,677	7,734
Cash and equivalents	578	711	1,465	1,537
Shareholders equity	23,099	28,055	33,339	37,706
Earnings per share (₹)	54.17	66.92	67.78	51.42

Not collected yet for this company: Dividend per share. These come from the filings, not the daily price feed.

Recent quarters

₹ crore · Most recent first

Quarter ended	Revenue	Operating profit	Net profit	EPS (₹)
30 Jun 2026	8,071	303	444	5.32
31 Mar 2026	7,516	83	221	2.65
31 Dec 2025	8,727	1,433	1,210	14.52
30 Sept 2025	8,805	1,787	1,437	—
30 Jun 2025	8,545	1,684	1,418	17.02
31 Mar 2025	—	—	—	19.10

Developments

0 positive · 5 negative

Reads negativeRegulatoryyesterday

USFDA Issues Two Observations After Records Assessment of Dr. Reddy's Mexico API Facility

Dr. Reddy's Laboratorieslarge cap

Medical Dialogues13 Sept 2026, 6:00 pm IST

Classification & context · Moves the numbers

The headline states a business fact and a direction that hurts it. This classifies the headline only, not the full article. It is not a recommendation.

Names an event that should show up in revenue, profit, debt, capacity or approvals.

Classifier confidence: 0.80. This is not the probability that the report is true.

Neutralyesterday

Dr. Reddy's Laboratories Limited rStock (RRDY) Price Prediction for 2026 to 2031

Dr. Reddy's Laboratorieslarge cap

Bybit13 Sept 2026, 8:50 am IST

Classification & context · Routine

No supported direction in the headline — that is not the same as unimportant. This classifies the headline only, not the full article. It is not a recommendation.

A real announcement — a product, a partnership, an appearance — that is unlikely to change the financials.

Classifier confidence: 0.35. This is not the probability that the report is true.

NeutralEarnings2 days ago

Best stocks to Buy: Axis Bank, Dr Reddy’s Labs, Indus Towers - Sumeet Bagadia recommends for Tuesday | Target, stop-loss

Axis Banklarge cap Dr. Reddy's LaboratoriesMentioned Indus TowersMentioned

Livemint12 Sept 2026, 3:36 pm IST

Classification & context · Moves the numbers

No supported direction in the headline — that is not the same as unimportant. This classifies the headline only, not the full article. It is not a recommendation.

Names an event that should show up in revenue, profit, debt, capacity or approvals.

Classifier confidence: 0.35. This is not the probability that the report is true.

Neutral2 days ago

Wellington Management Group LLP Cuts Position in Dr. Reddy's Laboratories Ltd $RDY

Dr. Reddy's Laboratorieslarge cap

marketbeat.com12 Sept 2026, 1:57 pm IST

Classification & context · Routine

No supported direction in the headline — that is not the same as unimportant. This classifies the headline only, not the full article. It is not a recommendation.

A real announcement — a product, a partnership, an appearance — that is unlikely to change the financials.

Classifier confidence: 0.35. This is not the probability that the report is true.

Reads negativeRegulatory2 days ago

Dr. Reddy’s Labs Receives Two USFDA Observations For Mexico API Facility Records Assessment

Dr. Reddy's Laboratorieslarge cap

Sahi12 Sept 2026, 10:44 am IST

Classification & context · Moves the numbers

The headline states a business fact and a direction that hurts it. This classifies the headline only, not the full article. It is not a recommendation.

Names an event that should show up in revenue, profit, debt, capacity or approvals.

Classifier confidence: 0.80. This is not the probability that the report is true.

Neutral2 days ago

Dr Reddy’s US food and drug administration inspection of Mexico facility ends with two observations

Dr. Reddy's Laboratorieslarge cap

Telegraph India12 Sept 2026, 9:35 am IST

Classification & context · Routine

No supported direction in the headline — that is not the same as unimportant. This classifies the headline only, not the full article. It is not a recommendation.

A real announcement — a product, a partnership, an appearance — that is unlikely to change the financials.

Classifier confidence: 0.35. This is not the probability that the report is true.

Reads negativeRegulatory2 days ago

Dr. Reddy’s Mexico API Plant Receives Two USFDA Observations

Dr. Reddy's Laboratorieslarge cap

Whalesbook12 Sept 2026, 5:59 am IST

Classification & context · Moves the numbers

The headline states a business fact and a direction that hurts it. This classifies the headline only, not the full article. It is not a recommendation.

Names an event that should show up in revenue, profit, debt, capacity or approvals.

Classifier confidence: 0.80. This is not the probability that the report is true.

NeutralRegulatory2 days ago

Dr Reddy’s Mexico API facility gets two observations from USFDA

Dr. Reddy's Laboratorieslarge cap

BusinessLine12 Sept 2026, 5:46 am IST

Classification & context · Moves the numbers

No supported direction in the headline — that is not the same as unimportant. This classifies the headline only, not the full article. It is not a recommendation.

Names an event that should show up in revenue, profit, debt, capacity or approvals.

Classifier confidence: 0.35. This is not the probability that the report is true.

Reads negativeRegulatory2 days ago

USFDA completes records assessment at Dr. Reddy's Mexico facility, issues two observations

Dr. Reddy's Laboratorieslarge cap

Business Upturn12 Sept 2026, 4:04 am IST

Classification & context · Moves the numbers

The headline states a business fact and a direction that hurts it. This classifies the headline only, not the full article. It is not a recommendation.

Names an event that should show up in revenue, profit, debt, capacity or approvals.

Classifier confidence: 0.80. This is not the probability that the report is true.

NeutralRegulatory2 days ago

Dr. Reddy’s: USFDA Completes Assessment at Mexico API Facility

Dr. Reddy's Laboratorieslarge cap

InvestyWise12 Sept 2026, 2:28 am IST

Classification & context · Moves the numbers

No supported direction in the headline — that is not the same as unimportant. This classifies the headline only, not the full article. It is not a recommendation.

Names an event that should show up in revenue, profit, debt, capacity or approvals.

Classifier confidence: 0.35. This is not the probability that the report is true.

Reads negativeRegulatory2 days ago

USFDA Issues Observations After Reviewing Dr. Reddy’s Mexico API Facility

Dr. Reddy's Laboratorieslarge cap

TipRanks12 Sept 2026, 1:57 am IST

Classification & context · Moves the numbers

The headline states a business fact and a direction that hurts it. This classifies the headline only, not the full article. It is not a recommendation.

Names an event that should show up in revenue, profit, debt, capacity or approvals.

Classifier confidence: 0.80. This is not the probability that the report is true.

NeutralRegulatory2 days ago

Dr Reddy's Mexico API facility gets 2 observations in US FDA records assessment

Dr. Reddy's Laboratorieslarge cap

CNBC TV1811 Sept 2026, 11:51 pm IST

Classification & context · Moves the numbers

No supported direction in the headline — that is not the same as unimportant. This classifies the headline only, not the full article. It is not a recommendation.

Names an event that should show up in revenue, profit, debt, capacity or approvals.

Classifier confidence: 0.35. This is not the probability that the report is true.

Neutral3 days ago

Dr. Reddy’s Laboratories Share Price Today (DRREDDY) | Live Chart, News & Stock Market

Divi's Laboratorieslarge cap Dr. Reddy's LaboratoriesMentioned

TechGraph11 Sept 2026, 6:42 pm IST

Classification & context · Routine

No supported direction in the headline — that is not the same as unimportant. This classifies the headline only, not the full article. It is not a recommendation.

A real announcement — a product, a partnership, an appearance — that is unlikely to change the financials.

Classifier confidence: 0.35. This is not the probability that the report is true.

Neutral3 days ago

Top Gainers & Losers, September 11, 2026 at 4:00 PM IST

Dr. Reddy's Laboratorieslarge cap

HDFC Sky11 Sept 2026, 4:33 pm IST

Classification & context · Routine

No supported direction in the headline — that is not the same as unimportant. This classifies the headline only, not the full article. It is not a recommendation.

A real announcement — a product, a partnership, an appearance — that is unlikely to change the financials.

Classifier confidence: 0.35. This is not the probability that the report is true.

Neutral3 days ago

Divi's Laboratories Share Price Today (DIVISLAB) | Live Chart, News & Stock Market

Dr. Reddy's Laboratorieslarge cap Divi's LaboratoriesMentioned

TechGraph11 Sept 2026, 4:08 pm IST

Classification & context · Routine

No supported direction in the headline — that is not the same as unimportant. This classifies the headline only, not the full article. It is not a recommendation.

A real announcement — a product, a partnership, an appearance — that is unlikely to change the financials.

Classifier confidence: 0.35. This is not the probability that the report is true.

Neutral3 days ago

Dr. Reddy's Laboratories rises Friday, outperforms competitors

Dr. Reddy's Laboratorieslarge cap

MarketWatch11 Sept 2026, 4:00 pm IST

Classification & context · Routine

No supported direction in the headline — that is not the same as unimportant. This classifies the headline only, not the full article. It is not a recommendation.

A real announcement — a product, a partnership, an appearance — that is unlikely to change the financials.

Classifier confidence: 0.35. This is not the probability that the report is true.

Neutral3 days ago

Top Gainers & Losers, September 11, 2026 at 12:00 PM IST

Dr. Reddy's Laboratorieslarge cap

HDFC Sky11 Sept 2026, 1:26 pm IST

Classification & context · Routine

No supported direction in the headline — that is not the same as unimportant. This classifies the headline only, not the full article. It is not a recommendation.

A real announcement — a product, a partnership, an appearance — that is unlikely to change the financials.

Classifier confidence: 0.35. This is not the probability that the report is true.

Neutral3 days ago

Dr. Reddy's Laboratories Share Price: valuation and peers

Divi's Laboratorieslarge cap Dr. Reddy's LaboratoriesMentioned

Univest11 Sept 2026, 11:59 am IST

Classification & context · Routine

No supported direction in the headline — that is not the same as unimportant. This classifies the headline only, not the full article. It is not a recommendation.

A real announcement — a product, a partnership, an appearance — that is unlikely to change the financials.

Classifier confidence: 0.35. This is not the probability that the report is true.

Neutral4 days ago

Dr. Reddy’s Issues New ESOP Shares After ADR Option Exercise

Dr. Reddy's Laboratorieslarge cap

TipRanks10 Sept 2026, 9:43 pm IST

Classification & context · Routine

No supported direction in the headline — that is not the same as unimportant. This classifies the headline only, not the full article. It is not a recommendation.

A real announcement — a product, a partnership, an appearance — that is unlikely to change the financials.

Classifier confidence: 0.35. This is not the probability that the report is true.

Neutral4 days ago

Dr. Reddy’s (NYSE: RDY) schedules analyst and investor meetings for September 2026

Dr. Reddy's Laboratorieslarge cap

Stock Titan10 Sept 2026, 8:59 pm IST

Classification & context · Routine

No supported direction in the headline — that is not the same as unimportant. This classifies the headline only, not the full article. It is not a recommendation.

A real announcement — a product, a partnership, an appearance — that is unlikely to change the financials.

Classifier confidence: 0.35. This is not the probability that the report is true.

About the business

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally. The company operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segment. Its Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids with the customer requirements. Its Others segment engages in developing therapies in the fields of oncology and inflammation; and research, development, and commercialization of differentiated formulations. The company offers its products for various therapeutic categories, including gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology, vaccines, vitamins and minerals, and pain management. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.

Industry: Drug Manufacturers - Specialty & Generic

www.drreddys.com

Data confidence

Prices, fundamentals and developments last verified 13 Sept 2026. Fundamentals are sourced from public filings feeds; interpretation is shown separately from figures.

See the Pharma & Healthcare sector →

Sign in to see the full financial record and classified developments

Guests see a sample. Members get every company, five-year fundamentals, classified developments, a watchlist and the decision journal.